AAAAAA

   
Results: 1-10 |
Results: 10

Authors: Rasmussen, T Fink-Jensen, A Sauerberg, P Swedberg, MDB Thomsen, C Sheardown, MJ Jeppesen, L Calligaro, DO DeLapp, NW Whitesitt, C Ward, JS Shannon, HE Bymaster, FP
Citation: T. Rasmussen et al., The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance, SCHIZOPHR R, 49(1-2), 2001, pp. 193-201

Authors: Christopoulos, A Grant, MKO Ayoubzadeh, N Kim, ON Sauerberg, P Jeppesen, L El-Fakahany, EE
Citation: A. Christopoulos et al., Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists, J PHARM EXP, 298(3), 2001, pp. 1260-1268

Authors: Shannon, HE Rasmussen, K Bymaster, FP Hart, JC Peters, SC Swedberg, MDB Jeppesen, L Sheardown, MJ Sauerberg, P Fink-Jensen, A
Citation: He. Shannon et al., Xanomeline, an M-1/M-4 preferring muscarinic cholinergic receptor agonist,produces antipsychotic-like activity in rats and mice, SCHIZOPHR R, 42(3), 2000, pp. 249-259

Authors: Rasmussen, T Sauerberg, P Nielsen, EB Swedberg, MDB Thomsen, C Sheardown, MJ Jeppesen, L Calligaro, DO DeLapp, NW Whitesitt, C Ward, JS Shannon, HE Bymaster, FP Fink-Jensen, A
Citation: T. Rasmussen et al., Muscarinic receptor agonists decrease cocaine self-administration rates indrug-naive mice, EUR J PHARM, 402(3), 2000, pp. 241-246

Authors: Thor, KB Muhlhauser, MA Sauerberg, P Shannon, H Springer, JP
Citation: Kb. Thor et al., Central muscarinic inhibition of lower urinary tract nociception, BRAIN RES, 870(1-2), 2000, pp. 126-134

Authors: Ahren, B Sauerberg, P Thomsen, C
Citation: B. Ahren et al., Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice, AM J P-ENDO, 40(1), 1999, pp. E93-E102

Authors: Bymaster, FP Shannon, HE Rasmussen, K DeLapp, NW Ward, JS Calligaro, DO Mitch, CH Whitesitt, C Ludvigsen, TS Sheardown, M Swedberg, M Rasmussen, T Olesen, PH Jeppesen, L Sauerberg, P Fink-Jensen, A
Citation: Fp. Bymaster et al., Potential role of muscarinic receptors in schizophrenia, LIFE SCI, 64(6-7), 1999, pp. 527-534

Authors: Shannon, HE Hart, JC Bymaster, FP Calligaro, DO Delapp, NW Mitch, CH Ward, JS Fink-Jensen, A Sauerberg, P Jeppesen, L Sheardown, MJ Swedberg, MDB
Citation: He. Shannon et al., Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats, J PHARM EXP, 290(2), 1999, pp. 901-907

Authors: Jeppesen, L Olesen, PH Hansen, L Sheardown, MJ Thomsen, C Rasmussen, T Jensen, AF Christensen, MS Rimvall, K Ward, JS Whitesitt, C Calligaro, DO Bymaster, FP Delapp, NW Felder, CC Shannon, HE Sauerberg, P
Citation: L. Jeppesen et al., 1-(1,2,5-thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M-1 agonists: Structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives, J MED CHEM, 42(11), 1999, pp. 1999-2006

Authors: Fink-Jensen, A Kristensen, P Shannon, HE Calligaro, DO Delapp, NW Whitesitt, C Ward, JS Thomsen, C Rasmusseen, T Sheardown, MJ Jeppesen, L Sauerberg, P Bymaster, FP
Citation: A. Fink-jensen et al., Muscarinic agonists exhibit functional dopamine antagonism in unilaterally6-OHDA lesioned rats, NEUROREPORT, 9(15), 1998, pp. 3481-3486
Risultati: 1-10 |